Entrada Therapeutics (TRDA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $4.78, +5.05% vs the prior close of $4.55.
- Volume 514.80K shares, 1.6x its 50-day average.
- New SEC filings: 8-K (Oct 14, 2026).
- No new insider buys or sales reported since the prior session.
TRDA jumps 5.1% to $4.78. Closed at $4.78, +5.05% vs the prior close of $4.55. Day range $4.43–$4.96, opened at $4.52.
TRDA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — TRDA jumps 5.1% to $4.78
- Closed at $4.78, +5.05% vs the prior close of $4.55. Day range $4.43–$4.96, opened at $4.52.
- Volume was 514.80K shares, 1.6x its 50-day average of 315.64K.
- Price is -27.9% vs its 50-day average ($6.63) and -47.4% vs its 200-day average ($9.08).
- 52-week range $4.11–$16.45; today's close sits at 5% of that range, 70.9% below the 52-week high.
Oct 14, 2026 — TRDA slides 6.4% to $4.55, a 52-week low on 2.4x normal volume
- Closed at $4.55, -6.38% vs the prior close of $4.86. Day range $4.11–$4.77, opened at $4.69.
- Volume was 740.10K shares, 2.4x its 50-day average of 314.10K — unusually heavy trading.
- Price is -31.9% vs its 50-day average ($6.68) and -50.0% vs its 200-day average ($9.11).
- 52-week range $4.11–$16.45; today's close sits at 4% of that range, 72.3% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 8-K.
Oct 13, 2026 — TRDA slides 11.6% to $4.86, a 52-week low
- Closed at $4.86, -11.64% vs the prior close of $5.50. Day range $4.83–$5.56, opened at $5.50.
- Volume was 255.20K shares, 0.8x its 50-day average of 319.01K.
- Price is -27.8% vs its 50-day average ($6.73) and -46.8% vs its 200-day average ($9.14).
- 52-week range $4.83–$16.45; today's close sits at 0% of that range, 70.5% below the 52-week high.
Oct 12, 2026 — TRDA dips 3.0% to $5.50
- Closed at $5.50, -3.00% vs the prior close of $5.67. Day range $5.48–$5.69, opened at $5.64.
- Volume was 198.60K shares, 0.6x its 50-day average of 322.09K.
- Price is -18.9% vs its 50-day average ($6.78) and -40.0% vs its 200-day average ($9.17).
- 52-week range $5.15–$16.45; today's close sits at 3% of that range, 66.6% below the 52-week high.
Oct 9, 2026 — TRDA rises 2.5% to $5.67
- Closed at $5.67, +2.53% vs the prior close of $5.53. Day range $5.44–$5.75, opened at $5.52.
- Volume was 209.40K shares, 0.6x its 50-day average of 329.79K.
- Price is -16.7% vs its 50-day average ($6.81) and -38.3% vs its 200-day average ($9.19).
- 52-week range $5.15–$16.45; today's close sits at 5% of that range, 65.5% below the 52-week high.
Oct 8, 2026 — TRDA dips 1.4% to $5.53
- Closed at $5.53, -1.43% vs the prior close of $5.61. Day range $5.25–$5.59, opened at $5.52.
- Volume was 361.50K shares, 1.1x its 50-day average of 331.27K.
- Price is -19.0% vs its 50-day average ($6.83) and -40.0% vs its 200-day average ($9.22).
- 52-week range $5.15–$16.45; today's close sits at 3% of that range, 66.4% below the 52-week high.
Oct 7, 2026 — TRDA jumps 3.5% to $5.61
- Closed at $5.61, +3.51% vs the prior close of $5.42. Day range $5.30–$5.66, opened at $5.33.
- Volume was 297.40K shares, 0.9x its 50-day average of 334.24K.
- Price is -18.1% vs its 50-day average ($6.85) and -39.3% vs its 200-day average ($9.24).
- 52-week range $5.15–$16.45; today's close sits at 4% of that range, 65.9% below the 52-week high.
Oct 6, 2026 — TRDA dips 1.1% to $5.42
- Closed at $5.42, -1.09% vs the prior close of $5.48. Day range $5.25–$5.52, opened at $5.52.
- Volume was 315.90K shares, 0.9x its 50-day average of 336.85K.
- Price is -20.9% vs its 50-day average ($6.85) and -41.5% vs its 200-day average ($9.27).
- 52-week range $5.15–$16.45; today's close sits at 2% of that range, 67.1% below the 52-week high.
Oct 5, 2026 — TRDA rises 1.9% to $5.48
- Closed at $5.48, +1.86% vs the prior close of $5.38. Day range $5.15–$5.48, opened at $5.38.
- Volume was 463.80K shares, 1.4x its 50-day average of 338.90K.
- Price is -20.2% vs its 50-day average ($6.87) and -41.1% vs its 200-day average ($9.30).
- 52-week range $5.15–$16.45; today's close sits at 3% of that range, 66.7% below the 52-week high.
Oct 2, 2026 — TRDA slides 5.3% to $5.38, a 52-week low
- Closed at $5.38, -5.28% vs the prior close of $5.68. Day range $5.17–$6.22, opened at $5.77.
- Volume was 463.70K shares, 1.3x its 50-day average of 345.47K.
- Price is -21.7% vs its 50-day average ($6.87) and -42.3% vs its 200-day average ($9.33).
- 52-week range $5.17–$16.45; today's close sits at 2% of that range, 67.3% below the 52-week high.
TRDA latest news & SEC filings
Every SEC filing by or about TRDA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 10, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mpm Bioventures 2018 Gp Llc sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- Mpm Bioventures 2018 Llc sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- Mpm Bioventures 2018, L.P. sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- Mpm Bioventures 2018 Gp Llc sold 192,500 shares at $7.41 (≈$1.43M) on Sep 8, 2026
- Mpm Bioventures 2018 Llc sold 192,500 shares at $7.41 (≈$1.43M) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mpm Bioventures 2018 (B), L.P. sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- Mpm Asset Management Investors Bv2014 Llc sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- Mpm Bioventures 2014 (B), L.P. sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- Gadicke Ansbert sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- Mpm Bioventures 2014, L.P. sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- Mpm Asset Management Investors Bv2018 Llc sold 28,837 shares at $7.13 (≈$205.61K) on Sep 9, 2026
- …plus 14 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $898.00K (prior year $1.95M) (-53.9% vs Jun 30, 2025)
- Net income: -$42.76M (prior year -$43.10M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.01 (prior year -$1.04) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade TRDA
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.43% (largest 11.6%). That is a volatile stock.
- Liquidity: about 354.88K shares (≈$1.70M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $4.78 vs a range of $4.11–$16.45 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Bioventures 2018 (B), L.P. Mpm sold 28,837 shares on Sep 9, 2026.
- Latest filings: 8-K Oct 14, 2026; 10-Q Aug 5, 2026; 8-K Aug 5, 2026.
- Share count: 38.94M shares outstanding (Jul 31, 2026), +2.4% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TRDA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 4.52 | 4.96 | 4.43 | 4.78 | 514.80K |
| Oct 14, 2026 | 4.69 | 4.77 | 4.11 | 4.55 | 740.10K |
| Oct 13, 2026 | 5.50 | 5.56 | 4.83 | 4.86 | 255.20K |
| Oct 12, 2026 | 5.64 | 5.69 | 5.48 | 5.50 | 198.60K |
| Oct 9, 2026 | 5.52 | 5.75 | 5.44 | 5.67 | 209.40K |
| Oct 8, 2026 | 5.52 | 5.59 | 5.25 | 5.53 | 361.50K |
| Oct 7, 2026 | 5.33 | 5.66 | 5.30 | 5.61 | 297.40K |
| Oct 6, 2026 | 5.52 | 5.52 | 5.25 | 5.42 | 315.90K |
| Oct 5, 2026 | 5.38 | 5.48 | 5.15 | 5.48 | 463.80K |
| Oct 2, 2026 | 5.77 | 6.22 | 5.17 | 5.38 | 463.70K |
| Oct 1, 2026 | 6.32 | 6.36 | 5.60 | 5.68 | 425.10K |
| Sep 30, 2026 | 6.20 | 6.39 | 6.12 | 6.35 | 239.90K |
| Sep 29, 2026 | 6.25 | 6.43 | 6.08 | 6.26 | 268.60K |
| Sep 28, 2026 | 6.13 | 6.24 | 5.93 | 6.22 | 442.60K |
| Sep 25, 2026 | 6.23 | 6.24 | 6.01 | 6.16 | 374.00K |
| Sep 24, 2026 | 6.47 | 6.47 | 6.14 | 6.22 | 319.10K |
| Sep 23, 2026 | 6.71 | 6.71 | 6.37 | 6.50 | 282.80K |
| Sep 22, 2026 | 6.71 | 6.93 | 6.65 | 6.71 | 195.50K |
| Sep 21, 2026 | 6.81 | 6.81 | 6.45 | 6.64 | 375.30K |
| Sep 18, 2026 | 6.85 | 6.89 | 6.60 | 6.75 | 354.40K |
About Entrada Therapeutics
Entrada Therapeutics (TRDA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1689375.
TRDA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gina Chapman | Director | Jun 12, 2026 |
| Dipal Doshi | CEO | Sep 3, 2026 |
| Peter S Kim | Director | Jun 12, 2026 |
| Kush Parmar | Director | Aug 10, 2026 |
| Maha Radhakrishnan | Director | Jun 12, 2026 |
| Mary Thistle | Director | Jun 12, 2026 |
| Bernhardt G Zeiher | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dipal Doshi | CEO | Sep 3, 2026 |
| Nathan J Dowden | President & COO | Sep 3, 2026 |
| Natarajan Sethuraman | President, Research & Develop. | Sep 3, 2026 |
| Kory James Wentworth | Chief Financial Officer | Sep 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 9, 2026 | Bioventures 2018 (B), L.P. Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Asset Management Investors Bv2014 Llc Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Bioventures 2014 (B), L.P. Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Ansbert Gadicke | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Bioventures 2014, L.P. Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Asset Management Investors Bv2018 Llc Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Todd Foley | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Bioventures 2014 Gp Llc Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Bioventures 2014 Llc Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Luke Evnin | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Bioventures 2018 Gp Llc Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Bioventures 2018 Llc Mpm | Sale | 28,837 | $7.13 |
| Sep 9, 2026 | Bioventures 2018, L.P. Mpm | Sale | 28,837 | $7.13 |
| Sep 8, 2026 | Bioventures 2018 (B), L.P. Mpm | Sale | 192,500 | $7.41 |
| Sep 8, 2026 | Asset Management Investors Bv2014 Llc Mpm | Sale | 192,500 | $7.41 |
TRDA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $25.42M | $-143.75M | -3.47 | $-128.51M |
| Dec 31, 2024 | $210.78M | $65.63M | 1.68 | $-41.56M |
| Dec 31, 2023 | $129.01M | $-6.68M | -0.20 | $139.80M |
| Dec 31, 2022 | — | $-94.62M | -3.02 | $-93.79M |
| Dec 31, 2021 | — | $-51.16M | -8.16 | $-50.86M |
Latest balance sheet: total assets $298.88M, total liabilities $65.47M, cash $99.28M (as of Jun 30, 2026).
TRDA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $7.06 |
| May 7, 2026 | 8-K Item 2.02 (results) | $6.85 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $12.79 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $10.52 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $6.95 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $5.95 |
| May 8, 2025 | 8-K Item 2.02 (results) | $8.62 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $11.98 |
| Jan 15, 2025 | 8-K Item 2.02 (results) | $12.25 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $18.62 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on TRDA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.